Mogamulizumab
Mogamulizumab Basic information
- Product Name:
- Mogamulizumab
- Synonyms:
-
- Mogamulizumab
- Research Grade Mogamulizumab (DHE85301)
- Mogamulizumab (anti-CCR4)
- KW-0761
- Research Grade Mogamulizumab
- CAS:
- 1159266-37-1
- MW:
- 0
- Mol File:
- Mol File
Mogamulizumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Mogamulizumab Usage And Synthesis
Uses
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL)[1][2][3].
in vivo
Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) together with PBMC transplantation inhibits the growth of EBV-positive NK-cell lymphomas in a murine xenograft model[2].
Mogamulizumab (0.1 mg/kg, i.v., every other day) together with canine PBMCs (every fourth day)), inhibits tumor growth in canine bladder cancer-engrafted mouse model[4].
Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4+CCR4+ T cells, with no adverse effect in dogs[4].
| Animal Model: | Murine xenograft model, constructed by using the immunodeficient NOG mouse and the EBV-positive NK-cell lymphoma cell line (SNK6)[2] |
| Dosage: | 1 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), together with PBMC transplantation; twice per week for 4 weeks. |
| Result: | Suppressed Tumor growth with vacuolar degeneration. |
IC 50
CCR4
References
[1] Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016 Jun;7(3):171-4. DOI:10.1177/2040620716636541
[2] Kanazawa T, et al. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Clin Cancer Res. 2014 Oct 1;20(19):5075-84. DOI:10.1158/1078-0432.CCR-14-0580
[3] Yamauchi J, et al. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy. J Infect Dis. 2015 Jan 15;211(2):238-48. DOI:10.1093/infdis/jiu438
[4] Maeda S, et al. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer. Cancer Immunol Res. 2019 Jul;7(7):1175-1187. DOI:10.1158/2326-6066.CIR-18-0751
MogamulizumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com